NEUROMYELITIS OPTICA

Safer biologics to treat Neuromyelitis Optica

neuromyelitis optica

(NMO)

Neuromyelitis Optica (NMO) is a rare disease and no treatment is currently approved by the FDA. Role of complement alternative pathway is certain in the disease. Alternative complement pathway not only results in tissue injury and cell death but also produces two potent anaphylatoxins C3a and C5a responsible for producing inflammatory molecules such as TNF-alpha, IL-1ß, IL-6, IL-7, IL-8, IL-17, IL-18 and VEGF.. Production of C3b via the AP is critical for disease conditions where cellular removal is part of the disease process. Production of C5b is important for complement's direct effect on cells causing cell death.
A therapeutic agent that selectively inhibits alternative pathway and prevents formation of C3b/C3a, C5b/C5a, and MAC is expected to provide therapeutic benefit in NMO.

NovelMed is developing antibody therapeutics to prevent cartilage loss, bone loss, and formation of osteophytes in OA. This would allow the re-build of cartilage and could provide benefits for OA.

It is estimated that there are more than 27 million OA patients in the United States alone. The Center for Disease Control and Prevention (CDC) forecasts that this number will double by 2020. OA is the most common form of arthritis and a leading cause of chronic disability, especially due to knee and/or hip dysfunction. No disease modifying treatments are available to provide benefit to chronic OA patients. Several small molecule drugs are used to manage symptoms, but these have no disease modifying effect. Direct administration of hyaluronic acid (HA) into the joint has at times demonstrated some patient benefit, but recent reports suggest otherwise. These facts imply that if a new safe and effective Disease Modifying Osteo Arthritis Drugs (DMOADs) is developed, the market is huge (~360 billion per year) and ready for acceptance.

Currently marketed drugs for OA occupy less than one-half of the total market. Our antibody therapeutics have demonstrated excellent efficacy in OA animal models. Based on our laboratory findings and associated pre-clinical data, our drug could have a transformational effect with better efficacy and safety than current options. Based on the mechanism of action, we believe it can be categorized under Disease Modifying OsteoArthritis Drugs (DMOADs).

Collaborate with novelmed